Preliminary Data: Anti-VEGF Eyedrop for Wet AMD Treatment Showed No Safety Concerns
No treatment-related adverse events have been reported in a phase 1/2 study evaluating the anti-VEGF eyedrop PAN-90806 (PanOptica) for the treatment of neovascular AMD. Anti-VEGF biological activity was observed in all monotherapy dose arms of the study. A full data set will be available in 2016.
According to the company’s president and CEO, Paul Chaney, PanOptica is developing an advanced, next-generation formulation of PAN-90806 for use in future trials. Mr. Chaney also reported that the company has initiated a phase 1 trial of PAN-90806 in patients with proliferative diabetic retinopathy.